In conclusion, our real‐life multicenter study confirmed GO‐based treatment efficacy with high MRD negativity rates in fit newly diagnosed de novo AML patients, especially in those with low genetic risk and CBF. This evidence concerns the gene CEBPZ and acute myeloid leukemia.